The news is directly about Regenxbio and is likely to impact its stock. While the Overweight rating suggests that Morgan Stanley expects the stock to outperform, the lowering of the price target may create some negative sentiment. However, as the reduction is minor, the overall impact is expected to be neutral in the short term.